AUTHORS
Lauryn Kelsey Bailey, MD, Julia Fecteau2, Jessica Maria Stempel, MD, MHS3, Kylee L. Martens, MD4, Chloe Chiu5, Corinne Lavasseur, MD6, Joseph Shatzel, MD7
AFFILIATIONS
1 Oregon Health & Science University, Portland, Oregon, United States
2 Oregon Health & Science University, Portland, Oregon, United States
3 Oregon Health & Science University, Portland, Oregon, United States
4 Oregon Health & Science University, Portland, Oregon, United States
5 Oregon Health & Science University, Portland, Oregon, United States
6 Oregon Health & Science University, Portland, Oregon, United States
7 Oregon Health & Science University, Portland, Oregon, United States
ABSTRACT
Background: Myelofibrosis (MF) is a Philadelphia chromosome-negative myeloproliferative neoplasm (MPN) clinically associated with a high risk of thrombotic and bleeding complications, and the only classical MPN for which an antiplatelet is not routinely recommended. Despite recognition of these competing risk factors, optimal strategies for thrombosis prevention in MF and their associated bleeding risks remain incompletely defined, particularly in the context of evolving disease-modifying therapies. The primary objective of our analysis is to identify disease-related factors and treatments associated with thrombotic risk in MF.
Methods: We conducted a large retrospective single-center cohort study evaluating predictors of venous and arterial thrombosis in patients with primary and secondary MF. This ongoing study involves individualized chart review of patients treated at Oregon Health & Science University from 2005-2025. The primary outcome includes venous or arterial thrombosis confirmed on imaging. Patient demographics, disease-modifying therapies, antithrombotic therapy, supportive treatments, MF driver mutation and mutational allele burden, thrombotic history, leukemic transformation, and all-cause mortality were collected. Univariable logistic regression was performed to evaluate candidate predictors of thrombosis, with clinically relevant and statistically significant variables included in multivariable models. Exact Poisson methods were used to estimate confidence intervals and compare incidence rates between treatment exposure and the overall post-diagnosis cohort. Time-varying Cox proportional hazards regression was used to assess the association between disease-modifying therapies and thrombotic risk, with medication exposure modelled as a time-varying covariate using documented treatment start and stop dates. Secondary outcomes included incident bleeding events, defined according to the International Society of Thrombosis and Haemostasis. Analyses of bleeding outcomes are ongoing.
Results: Of the 150 patients that met inclusion criteria, 40% (60/150) experienced at least one thrombotic event during their lifetime, and 21% (32/150) developed venous or arterial thrombosis after MF diagnosis. Most patients had a JAK2 mutation (100, 66.7%), followed by CALR (33, 22%) and MPL (7, 4.7%). Twelve patients had triple-negative MF (8%). On univariate and multivariate analysis (odds ratio with 95% confidence intervals for multivariate analysis shown), hypertension (OR 3.41, 95% CI 1.10-10.59, p=0.0341), body mass index (OR 1.10, 95% CI 1.02-1.18, p=0.0173), and white blood cell count (WBC) at diagnosis (OR 1.04, 95% CI 1.01-1.08, p=0.00667) were independent predictors of post-MF thrombosis. Overall thrombosis incidence was 3.76 events/100 person-years. Incidence rates of thrombosis during hydroxyurea and ruxolitinib exposure were 0.89 (95% CI 0.0224-4.94) and 2.71 (95% CI 1.17-5.33) events/100 person-years respectively, with neither differing significantly from the overall cohort. Time-varying Cox regression of the 32 post-MF thrombotic events likewise found no significant association between current treatment with hydroxyurea (p=0.284), ruxolitinib (p=0.925), and anticoagulation (p=0.890). Thrombotic risk did not differ significantly by anticoagulant therapy, antiplatelet therapy, type of cytoreduction (hydroxyurea or JAK inhibitor), risk stratification (DIPSS or MYSEC-PM), MF mutational allele burden, or disease status (primary- vs secondary-MF). History of venous and arterial thrombotic events were associated with numerically higher hazards of subsequent thrombosis, but were not statistically significant (p = 0.122). Bleeding events occurred in 25% of patients across their lifetime (38/150). Leukemic transformation occurred in 12% (18/150) of patients and all cause mortality was 33% (50/150).
Conclusions:
Our findings highlight the high rate of thrombosis in patients with MF, with more than 1 in 5 patients experiencing an event after MF diagnosis. WBC at diagnosis, body mass index, and hypertension were independently associated with thrombosis after MF diagnosis. Given that routine thromboprophylaxis is not recommended in the current MF guidelines, the thrombotic burden represents an important unmet clinical need. Future prospective studies should identify high-risk subgroups for whom targeted thromboprophylaxis strategies can be recommended to reduce thrombotic events while minimizing bleeding complications.
DISCLOSURES
Lauryn Kelsey Bailey, MD: No relevant conflicts of interest to declare.